COMMUNIQUÉS West-GlobeNewswire

Epinephrine Nasal Spray in Development for Treatment of Anaphylaxis Shows Promise as Potential Alternative to Intramuscular Injection
14/06/2018
PHOENIX, June 14, 2018 (GLOBE NEWSWIRE) -- Allergy sufferers who experience anaphylaxis—an acute, life-threatening allergic reaction requiring urgent treatment—may soon have a new delivery option for receiving a timely [...]
Rhythm Pharmaceuticals Completes Pivotal Enrollment in Two Ongoing Phase 3 Clinical Trials Evaluating Setmelanotide in Rare Genetic Disorders of Obesity
14/06/2018
One-Year Data from Cohorts of 10 Enrolled Patients to Support Concurrent New Drug Application (NDA) Filings in POMC and LEPR Deficiency Obesity BOSTON, June 14, 2018 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. ( [...]
Kura Oncology to Present at JMP Securities Life Sciences Conference
14/06/2018
SAN DIEGO, June 14, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that Troy Wilson [...]
CytomX Announces Appointment of Lloyd A. Rowland Jr. as General Counsel
14/06/2018
Brings 25 Years of Biotechnology and Pharmaceutical Legal Leadership Experience SOUTH SAN FRANCISCO, Calif., June 14, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX) a clinical-stage oncology-focused [...]
Dragon Jade to Engage ICR, Inc. for Strategic Investor Relations Services
14/06/2018
HONG KONG, June 14, 2018 (GLOBE NEWSWIRE) -- Dragon Jade International Limited (“Dragon Jade” or “the Company”) (OTCQX:DGJI), a provider of premier medical products and services, today announced that it has retained ICR [...]
Aptose Enters Into License Agreement With CrystalGenomics to Acquire CG-806 Rights in China
14/06/2018
Aptose adds China territory to its global rights; CrystalGenomics to receive upfront payment and future payments SAN DIEGO and SEOUL, South Korea, June 14, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO [...]
Trillium Therapeutics Doses First Patient With TTI-622, Its Second Immune Checkpoint Inhibitor Targeting CD47
14/06/2018
TORONTO, June 14, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that [...]
New Research from NRC Health and MetroHealth: Patients Willing to Switch Providers for Ease
14/06/2018
The latest white paper from NRC Health, produced in partnership with The MetroHealth System of Cleveland, finds that excellent care is not enough to earn patient loyalty—patients desire effortless experiences LINCOLN, [...]
CellAegis Announces Completion of Patient Enrollment in UK Investigator Sponsored Clinical Trial using autoRIC® Device
14/06/2018
TORONTO, June 14, 2018 (GLOBE NEWSWIRE) -- CellAegis Devices Inc. (“CellAegis” or the “Company”), a commercial-stage medical device company advancing innovative, non-invasive, safe and cost-effective solutions for acute [...]
Stemline Therapeutics Announces Three ELZONRIS™ (tagraxofusp; SL-401) Clinical Presentations, Including an Oral Presentation, at the EHA Congress
14/06/2018
NEW YORK, June 14, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced that ELZONRIS TM (tagraxofusp; SL-401) [...]
ContraFect to Present at JMP Securities Life Sciences Conference
14/06/2018
YONKERS, N.Y., June 14, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life- [...]
ProQR to Present at the JMP Life Sciences Conference
14/06/2018
LEIDEN, the Netherlands, June 14, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe [...]
Elite Pharmaceuticals, Inc. Announces Passing of Board Member Eugene Pfeifer
14/06/2018
NORTHVALE, N.J., June 14, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCQB:ELTP) today announced that a member of its Board of Directors, Eugene Pfeifer, passed away on Sunday, June [...]
Pluristem to Open Weekly Market Trading at TASE Following Positive Study Results
14/06/2018
HAIFA, Israel, June 14, 2018 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, is delighted to announce that it has been invited by [...]
Hydropothecary receives its first phase of licensing for 250,000 sq. ft. greenhouse expansion
14/06/2018
GATINEAU, Quebec, June 14, 2018 (GLOBE NEWSWIRE) -- The Hydropothecary Corporation (TSXV:THCX) (“Hydropothecary” or “The Company”) is pleased to announce that the first two zones of its 250,000 sq. ft. greenhouse [...]
Hydropothecary reçoit un permis pour les deux premières zones de son expansion de 250 000 pi2
14/06/2018
GATINEAU, Québec, 14 juin 2018 (GLOBE NEWSWIRE) -- La société Hydropothecary (TSXV:THCX) (« Hydropothecary » ou « la Société ») a le plaisir d’annoncer que la première phase de l’expansion de 250 000 pieds carrés de ses [...]
Nightstar Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for NSR-REP1 in Choroideremia
14/06/2018
First gene therapy RMAT designation for an inherited retinal disease STAR Phase 3 registrational trial ongoing and FDA interactions planned RMAT designation enables closer and more frequent multidisciplinary interaction [...]
Achillion to Present at the 2018 JMP Securities Life Sciences Conference
14/06/2018
NEW HAVEN, Conn., June 14, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Joseph Truitt, President and Chief Executive Officer of Achillion, will present at the 2018 JMP [...]
RavenQuest Announces Intent to Purchase Majority Stake in Elephant Extracts
14/06/2018
VANCOUVER, British Columbia, June 14, 2018 (GLOBE NEWSWIRE) -- RavenQuest BioMed Inc. (CSE:RQB) (the “ Company ” or “ RavenQuest ”) is pleased to announce that it has entered into a letter of intent with 1090252 B.C. [...]

Pages